Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

  • STATUS
    Recruiting
  • End date
    Nov 3, 2026
  • participants needed
    59
  • sponsor
    Novartis Pharmaceuticals
Updated on 21 April 2022
remission
graft versus host disease
cell transplantation
residual tumor
azacitidine
blast cells

Summary

The primary purpose of this study is to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with AML/secondary AML who are in complete remission with positive measurable residual disease post-allogeneic hematopoietic stem cell transplantation (MRD+ post-aHSCT), can enhance the graft versus leukemia (GvL) response and prevent or delay hematologic relapse without an unacceptable level of treatment-emergent toxicities, including clinically significant acute and/or chronic graft-versus-host disease (GvHD) and immune-related adverse events

Description

This is a phase Ib/II, open label, multi-center study of sabatolimab as monotherapy and in combination with azacitidine, in participants with AML/secondary AML who have received one aHSCT and achieved complete remission but MRD+, by local assessment, anytime between day 100 and day 365 post-aHSCT and at least 2 weeks after immunosuppressive medications have been tapered off.

The study will enroll approximately 59 participants and will be conducted in two parts:

Part 1 is a Safety Run-in of approximately 20 participants, to assess whether sabatolimab as monotherapy at the two tested dose levels (400 mg and 800 mg intravenously Q4W) is safe when administered in the post-aHSCT setting. For each dose level, once the required number of evaluable participants has been confirmed, enrollment will be halted until participants have completed the DLT observation period (≥ 8 weeks following the first dose). Following the observation period for DLTs, a Safety Review Meeting will be conducted after each dose level to assess safety and determine the recommended dose for expansion to proceed with enrollment of additional cohorts in Part 2 of the study.

Part 2 consists of sabatolimab monotherapy expansion cohort of approximately 13 participants, sabatolimab in combination with azacitidine cohort of approximately 20 participants, and an adolescent cohort of approximately 6 participants (≥ 12 years but < 18 years of age) with sabatolimab as monotherapy. Sabatolimab will be administered at the recommended dose for expansion determined in Part 1.

Details
Condition Acute Myeloid Leukemia
Treatment Azacitidine, Sabatolimab
Clinical Study IdentifierNCT04623216
SponsorNovartis Pharmaceuticals
Last Modified on21 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed informed consent must be obtained prior to participation in the study
At the date of signing the informed consent form (ICF), eligible participants must be ≥ 18 years for the adult cohorts; and ≥ 12 years old but < 18 years old for the adolescent cohort (cohort 5), which will open after completion of Safety Run-in
Diagnosis of AML/secondary AML and received one prior aHSCT performed to control AML
Participants in complete remission (< 5% bone marrow blasts, absence of circulating blasts, and absence of extramedullary disease) with measurable residual disease (MRD) positivity by local assessment, at any time between day 100 and day 365 after allogeneic stem cell transplantation
Ability to provide a fresh bone marrow aspirate sample collected within 28 days from enrollment/randomization, and immediately shipped to a Novartis designated central laboratory for MRD testing
Systemic GvHD (graft versus host disease) prophylaxis or treatment [immunosuppressive treatment (IST)] completely tapered for at least two weeks prior to study entry. Prednisone dose ≤ 5 mg/day or equivalent corticosteroid dose is allowed
Participants who are found with MRD positivity while still on or tapering systemic GvHD prophylaxis or treatment, MRD positivity must be re-confirmed at least 2 week after the last dose of IST
For the adult cohorts, participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
For the adolescent cohort, participants must have a Karnofsky (age ≥ 16 years) or Lansky
(age < 16 years) performance status score ≥ 50%

Exclusion Criteria

Prior exposure to TIM-3 directed therapy at anytime
History of severe hypersensitivity reactions to any ingredient of study drug(s)
(azacitidine, sabatolimab) or monoclonal antibodies (mAbs) and/or their excipients
Active acute GvHD grade III-IV according to standard criteria (Harris 2016)
Active Hepatitis B (HBV) or Hepatitis C (HCV) infection. Participants whose disease is
controlled under antiviral therapy should not be excluded
Active moderate chronic GvHD of the lungs according to NIH consensus criteria. Active
severe chronic GvHD according to NIH consensus criteria
History of another primary malignancy that is currently clinically significant or
currently requires active intervention
Other protocol defined inclusion/exclusion criteria may apply
Any concurrent severe and/or active uncontrolled infection requiring parenteral
antibacterial, antiviral or antifungal therapy (such as severe pneumonia, meningitis
or septicemia)
Active autoimmune disease requiring systemic therapy (e.g. corticosteroids). Topical
inhaled, nasal and ophthalmic steroids are not prohibited. Replacement corticosteroids
therapy is allowed and not considered a form of systemic treatment
Live vaccine administered within 30 days prior to the first day of study treatment
(Cycle 1 Day 1)
Other concurrent severe and/or uncontrolled medical conditions (e.g. uncontrolled
diabetes mellitus, chronic obstructive or chronic restrictive pulmonary disease
including dyspnoea at rest from any cause) or history of serious organ dysfunction or
disease involving the heart, kidney, or liver
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note